Lung Cancer
Conditions
Keywords
Early lung cancer, Photodynamic therapy, ENB
Brief summary
With the increased incidence of lung cancer and prevalence of low dose CT screening, treating of early lung cancer has becoming an important issue in the clinical practice of thoracic oncology. In this clinical study, the investigators will evaluate whether superDimension (superD) ENB (Electromagnetic navigation bronchoscopy) in combination with interstitial photodynamic therapy can provide the chance of tumor eradication.
Detailed description
Lung cancer is the one the major cause of cancer death all over the world especially in Asia. The prevalence of low dose CT screening has made more patients of lung cancer treated in the early stage. The treatment of choice for of early lung cancer is surgical resection. However, several difficulties exist in surgery for treating early lung cancer. eg. Some presenting as multi-focal lesions, which cannot be completely eradicated by surgical resection. Electromagnetic navigation bronchoscopy (ENB)（superDimension™ Navigation System, super-D ENB) is a novel technique, which uses an image guided localization system to direct steerable bronchoscopic tools to predetermined points within the bronchial tree. This technology allows improved access to peripheral lesions in particular. Photodynamic therapy (PDT) has been adopted an effective treatment option for the central located lung cancer by using photosensitizer which is focally retained in the tumor leading to tumor-specific abrasion by irradiating with a certain wave-length of light. The most frequently used and commercially available photosensitizer for lung cancer is PDT with Photofrin under 623 nm red light irradiation. For the peripheral lung cancer which cannot be approached by bronchoscopy, interstitial PDT with the aids of CT guided catheter implantation has been adopted. However, there are potential disadvantages of such approach including 1) bleeding or hemothorax during CT-guided catheter implantation; 2) dislodging of the catheter after lung collapse in the procedure; 3) unable to treat other lesion after pneumothorax. In the current proposal, the investigators use ENB in combination with PDT to handle to test the feasibility of super-D ENB guided-PDT to treat small lung cancer which cannot be eradicated through surgical resection.
Interventions
PROCEDUREsuper-D ENB guided-PDT
PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.
Sponsors
National Taiwan University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Multiple small lung cancer which cannot be completely removed by surgical resection. 2. Patient with small early lung cancer with diameter less than 1 cm and with high surgical risk precluding surgery. 3. Patient with small early lung cancer with diameter less than 1 cm but unwilling to receive surgical intervention. 4. Age above 20 years old and who can do the bronchoscopy test
Exclusion criteria
1\. Bleeding tendency. 2 .Poor cardiopulmonary function with intolerance to bronchoscopy examination.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival | 5 years | The time interval between enrollment and the earliest onset of any of the following events,: tumor local recurrence , distant metastasis, and mortality |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| post-operative complication | 3 month | defined as any deviation from the normal postoperative course |
| post-operative pulmonary function | 6, 12, and 24 months | the pulmonary function at 6, 12, and 24 months post-operation |
| overall survival | 5 years | The time interval between enrollment and death |
Countries
Taiwan
Contacts
Primary ContactJang-Ming Lee, MD. PhD.
Backup ContactPeiwen Yang, PhD.
Outcome results
None listed